Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians

Overview

Journal JNCI Cancer Spectr

Publisher Oxford University Press

Specialty Oncology

Date 2021 Feb 8

PMID 33554034

Citations 3

Authors

Courtney MacDonald

Danielle Mazza

Martha Hickey

Morgan Hunter

Louise A Keogh

kConFab Investigators

Sandra C Jones

Christobel Saunders

Stephanie Nesci

Roger L Milne

Sue-Anne McLachlan

John L Hopper

Michael L Friedlander

Jon Emery

Kelly-Anne Phillips

Affiliations

Soon will be listed here.

Abstract

Background: This study examined why women and doctors screen for ovarian cancer (OC) contrary to guidelines.

Methods: Surveys, based on the Theoretical Domains Framework, were sent to women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer and family physicians and gynecologists who organized their screening.

Results: Of 1264 Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer women, 832 (65.8%) responded. In the past 2 years, 126 (15.1%) had screened. Most of these (n = 101, 80.2%) would continue even if their doctor told them it is ineffective. For women, key OC screening motivators operated in the domains of social role and goals (staying healthy for family, 93.9%), emotion and reinforcement (peace of mind, 93.1%), and beliefs about capabilities (tests are easy to have, 91.9%). Of 531 clinicians 252 (47.5%) responded; a minority (family physicians 45.8%, gynecologists 16.7%) thought OC screening was useful. For gynecologists, the main motivators of OC screening operated in the domains of environmental context (lack of other screening options, 27.6%), and emotion (patient peace of mind, 17.2%; difficulty discontinuing screening, 13.8%). For family physicians,, the strongest motivators were in the domains of social influence (women ask for these tests, 20.7%), goals (a chance these tests will detect cancer early, 16.4%), emotion (patient peace of mind, 13.8%), and environmental context (no other OC screening options, 11.2%).

Conclusion: Reasons for OC screening are mostly patient driven. Clinician knowledge and practice are discordant. Motivators of OC screening encompass several domains, which could be targeted in interventions to reduce inappropriate OC screening.

Citing Articles

Using theories and frameworks to understand how to reduce low-value healthcare: a scoping review.

Parker G, Shahid N, Rappon T, Kastner M, Born K, Berta W Implement Sci. 2022; 17(1):6.

PMID: 35057832 PMC: 8772067. DOI: 10.1186/s13012-021-01177-1.

Peace of Mind: A Role in Unnecessary Care?.

Chen M, Hughes T, Dossett L, Pitt S J Clin Oncol. 2021; 40(5):433-437.

PMID: 34882501 PMC: 8824400. DOI: 10.1200/JCO.21.01895.

The Influence of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A Qualitative Study.

Pitt S, Saucke M, Roman B, Alexander S, Voils C Thyroid. 2021; 31(12):1800-1807.

PMID: 34641715 PMC: 8721509. DOI: 10.1089/thy.2021.0323.

References

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Skates S, Greene M, Buys S, Mai P, Brown P, Piedmonte M . Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res. 2017; 23(14):3628-3637. PMC: 5726402. DOI: 10.1158/1078-0432.CCR-15-2750. View

MacDonald D, Sarna L, Uman G, Grant M, Weitzel J . Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. Oncol Nurs Forum. 2006; 33(2):E27-35. DOI: 10.1188/06.ONF.E27-E35. View

Jacobs I, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi J . Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2015; 387(10022):945-956. PMC: 4779792. DOI: 10.1016/S0140-6736(15)01224-6. View

Mann G, Thorne H, Balleine R, Butow P, Clarke C, Edkins E . Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 2006; 8(1):R12. PMC: 1413975. DOI: 10.1186/bcr1377. View

Domchek S, Friebel T, Singer C, Evans D, Lynch H, Isaacs C . Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304(9):967-75. PMC: 2948529. DOI: 10.1001/jama.2010.1237. View

Atkins L, Francis J, Islam R, OConnor D, Patey A, Ivers N . A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implement Sci. 2017; 12(1):77. PMC: 5480145. DOI: 10.1186/s13012-017-0605-9. View

Gulliford M, Prevost A, Charlton J, Juszczyk D, Soames J, McDermott L . Effectiveness and safety of electronically delivered prescribing feedback and decision support on antibiotic use for respiratory illness in primary care: REDUCE cluster randomised trial. BMJ. 2019; 364:l236. PMC: 6371944. DOI: 10.1136/bmj.l236. View

Miller J, Baldwin L, Matthews B, Trivers K, Andrilla C, Lishner D . Physicians' beliefs about effectiveness of cancer screening tests: a national survey of family physicians, general internists, and obstetrician-gynecologists. Prev Med. 2014; 69:37-42. PMC: 4539137. DOI: 10.1016/j.ypmed.2014.07.009. View

10.

Fallowfield L, Fleissig A, Barrett J, Menon U, Jacobs I, Kilkerr J . Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer. 2010; 103(4):454-61. PMC: 2939792. DOI: 10.1038/sj.bjc.6605809. View

11.

C Grossman D, Curry S, Owens D, Barry M, Davidson K, Doubeni C . Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(6):588-594. DOI: 10.1001/jama.2017.21926. View

12.

Rebbeck T, Lynch H, Neuhausen S, Narod S, Veer L, Garber J . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002; 346(21):1616-22. DOI: 10.1056/NEJMoa012158. View

13.

Ragland M, Trivers K, Andrilla C, Matthews B, Miller J, Lishner D . Physician Nonprofessional Cancer Experience and Ovarian Cancer Screening Practices: Results from a National Survey of Primary Care Physicians. J Womens Health (Larchmt). 2018; 27(11):1335-1341. PMC: 6657773. DOI: 10.1089/jwh.2018.6947. View

14.

Baldwin L, Trivers K, Matthews B, Andrilla C, Miller J, Berry D . Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?. Ann Intern Med. 2012; 156(3):182-94. DOI: 10.7326/0003-4819-156-3-201202070-00006. View

15.

Isaacs C, Peshkin B, Schwartz M, DeMarco T, Main D, Lerman C . Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treat. 2002; 71(2):103-12. DOI: 10.1023/a:1013800409238. View

16.

Finch A, Lubinski J, Moller P, Singer C, Karlan B, Senter L . Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014; 32(15):1547-53. PMC: 4026578. DOI: 10.1200/JCO.2013.53.2820. View

17.

Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View

18.

Daly M, Pilarski R, Axilbund J, Buys S, Crawford B, Friedman S . Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014; 12(9):1326-38. DOI: 10.6004/jnccn.2014.0127. View

19.

McDonagh M, Peterson K, Winthrop K, Cantor A, Lazur B, Buckley D . Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018; 46(8):3337-3357. PMC: 6134646. DOI: 10.1177/0300060518782519. View

20.

Holman L, Lu K, Bast Jr R, Hernandez M, Bodurka D, Skates S . Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2013; 210(3):257.e1-6. PMC: 4001707. DOI: 10.1016/j.ajog.2013.11.022. View